NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Xylyx Bio, a pioneer in tissue-specific extracellular matrix biomaterials, today announced the development of substrates for anti-fibrotic drug discovery as the next stage of its pipeline of pre-clinical cell culture products.
Through the development of fibrosis-specific in-vitro substrates, Xylyx Bio aims to support drug discovery and development for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH). Xylyx Bio is actively partnering with leading pharmaceutical companies to support deeper understanding of fibrosis biology and develop fibrosis-specific platforms for high-throughput screening and has signed an agreement with Boehringer Ingelheim, which is actively researching this area.
Fibrotic disorders contribute to an estimated 45% of all-cause mortality in the USA, and effective therapies are limited due to the high failure rate of drug candidates in clinical trials. Although predictive in-vitro models of fibrotic disease for pharmaceutical drug development hold potential to reduce attrition and accelerate approval of effective drugs, conventional cell-based models are not reflective of human disease. This persistent gap represents a major challenge to successfully developing lifesaving drugs. The availability of more physiologic cell models holds great potential to significantly improve in-vitro models and help accelerate the development of new therapeutics.
"Current in-vitro models poorly mimic fibrosis biology, and thus are of limited value in anti-fibrotic drug development," explained John O'Neill, Chief Scientific Officer of Xylyx Bio. "Our fibrosis-specific extracellular matrix products benefit drug discovery programs by enabling drug candidates to be investigated in a disease-relevant in-vitro environment that recapitulates human fibrosis, yielding new insights into fibrotic mechanisms and guiding decision-making through therapeutic development."
About Xylyx Bio
Xylyx Bio extracellular matrix substrates provide the full suite of matrix components in the natural cell microenvironment, supporting the most accurate and actionable results for scientists working in pharmaceutical development, cell biology research, and regenerative medicine. To learn more, visit xylyxbio.com.
Xylyx Bio, Inc.
Tanya Yankelevich, Director of Product Management
SOURCE Xylyx Bio